Home > Investor Relations
Achillion is focused on solutions for the most challenging problems in infectious disease.
The investor pages that follow are your resource for financial information about Achillion Pharmaceuticals. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.
Nov 8, 2014
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
Nov 6, 2014
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology